Shire’s Ornskov Not Planning Quick Hires To Fill Top Leadership Ranks
This article was originally published in The Pink Sheet Daily
Incoming Shire CEO Flemming Ornskov made his debut before the rare disease community by delivering a keynote address at the World Orphan Drug Congress. Afterwards, he talked about the management transition at his new company and challenges in orphan drug development.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.